GSK Lowers Vaccine Sales Forecast Amid Q3 Decline

GSK's sales for its RSV vaccine, Arexvy, plummeted by 72% in Q3 2024 to £188 million, as the US Advisory Committee on Immunisation Practices limited recommendations for its use. This decline followed a previous strong launch and was compounded by weaker RSV circulation and a focus on COVID-19 vaccinations. Similarly, sales for the shingles vaccine Shingrix dropped 7% to £739 million, both figures falling short of analyst expectations. In response, GSK has cut its 2024 vaccine sales forecast for the second time this year, now anticipating low-single-digit percentage declines instead of growth. Despite these challenges in the vaccine sector, GSK reported an overall revenue increase of 2% and maintained a positive outlook for its broader operations, bolstered by strong performance in specialty medicines. The disappointing vaccine results have negatively impacted GSK's share price, which has fallen nearly 12% over the past six months.